This protocol uses lower initial doses of compounded semaglutide designed to reduce nausea and other side effects while still engaging your appetite-regulation pathways
I cant remember one that didnt have at least a mentionif not an entire sessionregarding GLP-1s impact on healthcare costs to employers and Americans in general
Semaglutide Not Associated with Increased Risk of Eye Disorders, 19 August 2025, The use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION), 27 June 2025, WHO, PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy, 06 June 2025, European Medicine Agency, Kai-Yang Chen, Hoi-Chun Chan, Chi-Ming Chan, does semaglutide increase the risk of non-arteritic anterior ischemic optic neuropathy
Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies
In the MitoPark PD mice, in which mitochondrial function is impaired in the dopaminergic neurons, PT320, a sustained release formulation of the GLP-1RA exenatide, reduced ROS production and improved tyrosine hydroxylase expression
